latest update:
[TrialBase DB]

trial summary · NCT07631325

Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma

A Phase II Trial of MOR Antagonism With Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma (MORALE-MM)

Trial record from the TrialBase DB dataset, status RECRUITING, condition Unresectable Cutaneous Melanoma, sponsored by John Kirkwood. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07631325phase PHASE1/PHASE2enrollment 28start 2026-11-30

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This first-in-human study will evaluate the safety, clinical activity, and immunologic effects of combining axelopran with nivolumab in patients with PD-1-refractory unresectable or metastatic cutaneous melanoma. Exploratory analyses incorporating opioid exposure history and post-hoc OPRM1 genotyping will inform future precision immuno-oncology strategies.

Source record: https://clinicaltrials.gov/study/NCT07631325

Facts

registry idNCT07631325
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionUnresectable Cutaneous Melanoma
sponsorJohn Kirkwood
sponsor classOTHER
enrollment28
start date2026-11-30
primary completion2028-07-31
completion2030-07-31
results postednot reported

Conditions

  • Unresectable Cutaneous Melanoma

Interventions

  • Axelopran
  • Nivolumab

Countries

  • United States

Intervention types: DRUG

Work with this record